At 6.1% CAGR, the MEA Intravenous Immunoglobulin Market is projected to be worth US$ 711.99 million by 2028, says Business Market Insights              

According to Business Market Insights’ research, the MEA intravenous immunoglobulin market was valued at US$ 497.97 million in 2022 and is expected to reach US$ 711.99 million by 2028, registering a CAGR of 6.1% from 2022 to 2028. Strong pipeline candidates for IVIG and rising prevalence of immunodeficiency diseases are the critical factors attributed to the market expansion.                

Leading players in the intravenous immunoglobulin market have multiple projects and many biological products in pipelines based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is in the process of developing portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG would become the trend in the intravenous immunoglobulin market in the future.

On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of MEA intravenous immunoglobulin market.    

• Based on type, the MEA intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 29.0% market share in 2022, amassing US$ 144.39 million. It is projected to garner US$ 204.96 million by 2028 to expand at 6.0% CAGR during 2022–2028.  
• Based on application, the MEA intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.5% market share in 2022, amassing US$ 107.11 million. It is projected to garner US$ 158.10 million by 2028 to expand at 6.7% CAGR during 2022–2028.
• Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.4% market share in 2022, amassing US$ 276.00 million. It is projected to garner US$ 391.63 million by 2028 to expand at 6.0% CAGR during 2022–2028.
• Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.4% market share in 2022, amassing US$ 235.86 million. It is projected to garner US$ 332.19 million by 2028 to expand at 5.9% CAGR during 2022–2028.
• Based on country, the MEA intravenous immunoglobulin market is segmented into South Africa, Saudi Arabia, UAE, and the Rest of MEA. Our regional analysis states that Saudi Arabia captured 44.2% market share in 2022. It was assessed at US$ 220.31 million in 2022 and is likely to hit US$ 311.72 million by 2028, exhibiting a CAGR of 6.0% during the forecast period.    

Key players dominating the MEA intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited, among others.  

• In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs.

• In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com